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The Lennox-Gastaut syndrome (LGS), one of the most difficult epilepsy 
syndromes to treat, is characterized by a triad of intractable seizures of various 
types, a slow (< 2.5-hertz) spike-wave pattern in EEG and mental retardation. 
The aim of this study was to evaluate the efficacy and safety of lamotrigine as 
add-on therapy in intractable epilepsy of children with LGS. 
Materials & Methods
In a quasi- experimental study, 40 children with LGS referred to the pediatric 
neurology clinic of Shaheed Sadoughi Hospital in Yazd, between August 2007 
and to November 2008, were evaluated.
Results
Twenty-two boys and 18 girls with a mean age of 4.12 ± 1.8 years were evaluated. 
At the end of three months of treatment with lamotrigine, 12 % were seizure 
free, 52% had> 50% reduction in seizure frequency and 12% had increase in 
seizures. Means of seizure frequency/per week, before and after treatment were 
70 (range 1-180) and 18.6 (range 0-60) respectively, indicating effectiveness of 
the drug in seizure reduction (P value = 0.003). The drug was effective in 72 % 
of mixed type seizures, 40 % of generalized tonic-clonic and 33% of drop attack 
and tonic seizures. Transient side effects were seen in 12.5 % (drowsiness in 3 
and ataxia in 2 children). No serious side effects were seen. 
Conclusion
Lamotrigine should be considered as an add-on therapy in management of 
intractable epilepsy in LGS.
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Introduction 
Lennox-Gastaut syndrome (LGS) is one of the catastrophic epileptic syndromes of 
childhood. “William Lennox described the clinical features of the syndrome in 1930s, 
followed by Lennox and Davis’ report of the symptomatic triad of the syndrome. 
Later, Gastaut expanded on the original observations of Lennox and Davis” (1). 
This syndrome is characterized by the triad of intractable seizures of various types, 
particularly tonic and atonic seizures; it also includes absence and myoclonic 
seizures (atypical petit mal) as well as nonconvulsive status epilepticus, a slow (less 
than 2.5-hertz) spike-wave pattern on the interictal EEG that is generalized and of 
highest voltage in the frontal region (also called an atypical spike and wave pattern) 
and mental retardation (occasionally progressive) with or without other neurologic 
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abnormalities (2).
LGS accounts for 3-10 percent of all cases of childhood 
epilepsy but it is a major contributor to morbidity and 
seizures that are often associated with falls and injuries 
(3). Although seizure onset varies from 6 months to 16 
years, in two-thirds of cases, the onset occurs between 2 
and 14 years of age (4).
Etiologic classification of LGS
1. Primary or idiopathic 
2. Secondary or symptomatic:
• Prenatal: Cerebral dysgenesis, tuberous sclerosis, 
congenital infections, stroke
• Perinatal: Hypoxia/ischemia, intracranial hemorrhage 
• Postnatal: CNS infections, Postinfectious process, 
Hypoxia/ischemia, cerebral vascular disease, head 
injury, hypoglycemia, and degenerative disorders (5).
In approximately 40% of affected children, a known 
cause cannot be identified, although increasingly, these 
children are found to have genetic disorders, particularly 
chromosomal syndromes (6). Symptomatic LGS has 
worse prognosis than cryptogenic etiology (7). Medical 
management of LGS is often difficult and seizures are 
mainly drug resistant. Complete recovery, seizure-free 
with normal development is very unusual in LGS. The 
optimal therapy is uncertain and may depend in part 
upon the underlying etiology. Main treatment is based on 
antiepileptic drugs (AEDs) and some children may need 
more than one mode of treatment (8). Other methods for 
treatments of refractory seizures include the ketogenic 
diet and surgical options, which include vagus nerve 
stimulation, corpus callosotomy, stereotactic surgical 
implantation of electrodes to the centromedian nuclei of 
the thalamus, etc (6,8, 9).
Different drugs are used as the first-line agents in LGS 
treatment such as valproate (10), zonisamide, topiramate 
(11) and clonazepam (12). 
Other antiepileptic drugs such as lamotrigine(1,6,8,13-
16), felbamate (6,8,14,16), benzodiazepines and 
phenobarbiturates(1,8) and prednisone (17) have been 
used in LGS. On the other hand, carbamazepine can 
precipitate drop attacks in some of these children. No 
single treatment regimen could be considered superior 
to others, and no study to date has shown any one drug 
to be highly efficacious (6). It is difficult to provide 
recommendations for the treatment of LGS in the absence 
of comparative trials. Therefore, AEDs with greater 
efficacy and fewer side effects are urgently needed. 
Management depends on the response of patients and 
we are often forced to use two or more kinds of AEDs in 
combination. 
Lamotrigine (LTG), initially approved in 1994 for 
the adjunctive treatment of generalized seizures of 
LGS in children aged over 2 years (13), is one of new 
antiepileptic which acts as voltage-sensitive sodium 
channel to stabilize neuronal membranes and presynaptic 
inhibition of  excessive release of excitatory amino acids, 
particularly glutamate and aspartate. LTG suppresses 
postsynaptic AMPA (alpha-amino-3-hydroxy-5-methyl-
4-isoxazole propionic acid) receptors and reduces 
glutamate release in granule cells of dentate gyrus. The 
postsynaptic effect can also be one of the underlying 
mechanisms of LTG (18).
Guidelines issued by the American Academy of 
Neurology (AAN) state that LTG can be used as initial 
therapy in patients with newly diagnosed partial epilepsy 
and idiopathic generalized epilepsy, as well as mixed 
seizure disorders (19).
The purpose of this study was to evaluated the efficacy 
and safety of LTG in all types of seizures among children 
with LGS in Yazd, Iran.
Materials & Methods 
This quasi- experimental (before and after) study was 
conducted on children with LGS and refractory epilepsy 
referred to pediatric neurology clinic of Shaheed 
Sadoughi Medical Sciences university from August 
2007 to November 2008 in Yazd, Iran.
The diagnostic criteria for the LGS in this study were 
based on the International League Against Epilepsy 
(ILAE) classification (20,21). In fact the patients were 
considered as the control group (before) and the case 
group (after) LTG treatment. Care was taken to include 
LGS patients aged 1-18 years, having had at least one 
seizure/week, not responding to an adequate dosage of at 
least two conventional AEDS (in single or combination), 
and last not having used LTG before. 
Information collected at baseline included demographic 
data and epilepsy characteristics such as etiology, age 
of onset, type and frequency of seizures and AEDS 
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history. Results of physical and neurologic examination, 
laboratory analysis, EEG and brain CT scan or MRI 
were included. Laboratory blood analysis, both at the 
initiation of the study and three months after treatment 
included assessment of calcium, urea, creatinine, alanine 
aminotransferase, aspartate aminotransferase and 
complete blood count.
The trial had three phases as given
1. Baseline phase : Seizure frequency was recorded for a 
period of 3 months before adding LTG.
2. Titration phase: To minimize side effects of the drug, 
LTG was added to the previous AEDS regimen in a 
4 week period as follows: 1, 2, 3, 5 mg / kg / day in 
patients who had taken valproic acid simultaneously, 
and 3, 5, 7, 10 mg / kg / day in those without valproic 
acid usage 
3. Maintenance phase: Maximum dose or that which 
controlled seizures was continued for 3 months. No 
new AEDS were added to LTG and concomitant 
drugs, but the dose of the concomitant could be 
increased or decreased. Patients were visited for 
three consecutive months to document clinical 
information related to their parents, the types 
and numbers of seizures, drug side-effects and 
paraclinical investigations. At the end of the period, 
LTG efficacy and safety were evaluated. Seizure 
frequency/ month was compared to that of 3 months 
before and after LTG use and was used the following 
classification: 
1. Seizure free: Total cessation of seizures
2. Improved: Over 50 % reduction in seizure frequency
3. Unchanged: No notable change witnessed in seizure 
frequency
4. Worsened: Over 25% increase in seizure frequency
We compared means of seizure frequency before and after 
treatment using the paired-samples t-test. X2 analysis 
was used for data analysis of qualitative variables and 
differences were considered significant at P<0.05.
 This study has been approved by the ethics committee of 
the Shaheed Sadoughi University of Medical Sciences, 
Yazd, Iran. 
Results
LTG efficacy was evaluated in intractable seizures of 
45 children with LGS. Three patients were excluded for 
poor compliance. Coetaneous drug rash was seen in 2 of 
the patients, one or two weeks after LTG consumption 
that resolved with discontinuation of LTG and there 
was no need for hospitalization; these two patients were 
excluded from the study but included only in safety 
analysis. Eventually 22 boys (55%) and 18 girls (45%) 
with a mean age of 4.5 ± 2.9 years (range 1-14 yr) were 
evaluated.
Age of onset for seizures ranged between 7 months to 2 
years (mean 0. 9 yr). From the viewpoint of major seizure 
types, 29 children (72.5 %) showed mixed type (more 
than of one type of seizure), five (12.5 %) generalized 
tonic-clonic seizure (GTCS), three (7.5 %) drop attack 
and three tonic (7.5%).
Seizures were not controlled despite usage of 4 -12 
(mean= 6.4) antiepileptic drugs. 
Based on the etiologic classification of LGS, 22 (55%) 
were symptomatic and 18 (45 %) were idiopathic. 
Neuroimaging results were normal in 24 (60 %) of 
children. 
Results of the efficacy analysis are shown in table 1, 
which indicates good response to lamotrigine, with 
either complete cessation of seizures, or  > 50 % 
reduction in seizure frequency being observed in 64% 
of patients. Mean of seizure frequency/week, before and 
after treatment were 70(range1-180) and 18.6(range0-
60) respectively, demonstrating the efficacy of LTG. 
(Confidence interval 95%, t =3.5, p value 0.003) 
Good responses were seen in 72% (21/29) of mixed 
type, 40% (2/5) of GTCS, 33% (1/3) of drop attack and 
in 33% (1/3) of tonic seizures. For statistical analysis, 
GTCS, drop attack and tonic seizures were considered 
as generalized seizures.
Table 2 shows effectiveness of LTG on seizure types and 
etiologic classes of LGS and indicates that drug efficacy 
did not differ in types of seizure and in etiologic classes 
of LGS.
The mean dosage of LTG for seizure control was 8.7 
mg/Kg/day (range: 3-10). Transient and mild side effects 
were seen in 12.5% (N=5) of patients; drowsiness 
in 7.5% (n=3) and ataxia in 5% (n=2), all of which 
disappeared in one or two weeks. No serious adverse 
events such as hematologic abnormality, hepatotoxicity 
or nephrotoxicity were observed.
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Table 1. Efficacy results of lamotrigine after three months
Efficacy resultNumberPercent
Seizure free512
> 50% reduction of seizure frequency 2152
No notable change witnessed in seizure frequency923
Worsened (seizure frequency increased > 25 %)512
Total40100
Table 2. Effectiveness of LTG on seizure types, etiologic classification
Data
Good response Not response
P-value
Number Percent Number Percent
Seizure types
Generalized 5 45 6 55
0.11
Mixed 21 72 8 28
LGS etiologic 
classification
Symptomatic 12 55 10 45
0.436
Idiopathic 12 67 6 33
Discussion
Lamotrigine efficacy and safety in seizures of children 
with LGS were evaluated in the current study and a 
good response to LTG was seen in 64 % of patients with 
Lennox - Gastaut syndrome, findings consistent with 60 
% result of two other studies (22,23); however in other 
studies, this rate varied between 33 % and 91% (22-25), 
which may be explained by ethnical and geographic 
differences, duration of follow up, pharmacokinetic 
aspects, methods of patients selection, etc. 
According to the results of the study, lamotrigine was 
a useful add-on therapy in treating epilepsy in children 
with LGS, findings in agreement with those of several 
other studies (14,15,22, 25); in a study from Taiwan, 
LTG was found to have excellent response in patients 
after ineffective callosotomy (26). 
In this study, the drug was effective in 40 % of patients 
with GTCS. In Motte et al study, over 50 % reduction in 
seizure frequency was seen in 43 % of GTCS of LGS 
children (25). In another study 72% of patients aged 
2 - 55 years with primary GTCS experienced a ≥ 50% 
reduction in frequency of seizures (27).
In this study, erythematous skin rash was seen in 5 % 
(2/42) of patients but in other studies, this rate varied 
between 3-17% (11,22,28,29) The frequency of rash 
increases with more rapid titration and concomitant 
valproate; hence it is recommended to start LTG with 
low dose and slow titration. However, none of our 
patients had concomitant valproate or high drug dose, 
and skin rash was seen in them in the first or second 
week of treatment, which could be due to differences in 
race or drug pharmacokinetics. 
In the present study, the most common side effect was 
drowsiness, a finding similar to those of other studies 
(27,30,31). Headache was not seen in any of our 
patients, but was a common side effect documented in 
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other studies (30-33). 
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